证券代码：002432 证券简称：九安医疗 公告编号：2025-078 天津九安医疗电子股份有限公司 回购报告书 本公司及董事会全体成员保证信息披露内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、天津九安医疗电子股份有限公司（以下简称"公司"）于2025年10月13 日召开第六届董事会第二十七次会议审议通过了《关于公司回购股份方案的议 案》。本次回购股份方案在董事会决策权限之内，无需提交股东大会审议。 2、回购方案的主要内容： 本次回购的资金总额不低于3亿元人民币(含)且不超过6亿元人民币(含)。本 次回购股份的价格为不超过人民币53.5元/股（含），若按回购资金总额上限和回 购股份价格上限进行测算，预计可回购股份数量约为11,214,953股，约占公司当 前总股本的2.41%；按回购资金总额下限和回购股份价格上限测算，预计可回购 股份数量约为5,607,477股，约占公司当前总股本的1.21%。本次回购股份用于维 护公司价值及股东权益而出售。回购股份方案在董事会审议权限内，无需提交股 东大会审议，回购的实施期限为自公司董事会审议通过最终回购股份方案之日起 不超过3个月。 具 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-077 天津九安医疗电子股份有限公司 | 序号 | 股东名称 | 持股数量（股） | 占公司最新总股 | | --- | --- | --- | --- | | | | | 份比例（%） | | 1 | 石河子三和股权投资合伙企业（有限合伙） | 116,544,519 | 25.07 | | 2 | 天津九安医疗电子股份有限公司回购专用证券账户 | 35,253,634 | 7.58 | | 3 | 天津九安医疗电子股份有限公司－2024 年员工持股 | 17,823,672 | 3.83 | | | 计划 | | | | 4 | 中国银行股份有限公司－华宝中证医疗交易型开放 | 9,520,914 | 2.05 | | | 式指数证券投资基金 | | | | 5 | 天津九安医疗电子股份有限公司－2022 年员工持股 | 6,433,800 | 1.38 | | | 计划 | | | | 6 | 喻荣虎 | 6,392,160 | 1.37 | | 7 | 中国农业银行股份有限公司－中证 交易型开放 500 | 4,813,676 | 1.0 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300007 | 汉威科技 | 53.32 | -6.51% | 25.35万 | 13.99亿 | | 301117 | 佳塚科技 | 35.16 | -5.28% | 4.93万 | + 1.79亿 | | 002230 | 科大讯飞 | 52.90 | -4.55% | C 86.81万 | 47.01亿 | | 300341 | 麦克圆迪 | 18.22 | -4.00% | 20.20万 | 3.77亿 | | 300573 | 兴齐眼药 | 65.67 | -3.75% | 9.39万 | 6.30 Z | | 002262 | 图华药业 | 25.52 | -3.70% | 17.70万 | 4.58亿 | | 300020 | ST银江 | 3.50 | -3.58% | 18.04万 | 6470.81万 | | 300049 | 福瑞股份 | 66.11 | -3.49% | 9.34万 | 6.39 Z | | 600718 ...

Market Overview - The medical device sector experienced a decline of 0.96% on October 14, with Hualan Co. leading the drop [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Top Performers - Yingke Medical (300677) saw a significant increase of 12.69%, closing at 43.52 with a trading volume of 463,500 shares and a turnover of 1.963 billion [1] - Zhend Medical (603301) rose by 9.02%, closing at 65.89 with a trading volume of 151,400 shares and a turnover of 980 million [1] - Other notable gainers include JinHao Medical (920925) up 5.80%, Jiuan Medical (002432) up 4.06%, and Canar Co. (301122) up 3.47% [1] Underperformers - Hualan Co. (301093) fell by 6.45%, closing at 37.26 with a trading volume of 40,800 shares and a turnover of 157 million [2] - Aohua Endoscopy (688212) decreased by 5.64%, closing at 48.20 with a trading volume of 32,100 shares and a turnover of 159 million [2] - Other significant declines include Maike Aodi (300341) down 4.00% and Huachuang Technology (688151) down 3.57% [2] Capital Flow - The medical device sector saw a net outflow of 173 million from institutional investors, while retail investors experienced a net inflow of 69.34 million [2] - The sector's capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Sainuo Medical (688108) had a net inflow of 23.6 million from institutional investors, but a net outflow of 21.46 million from retail investors [3] - Yingke Medical (300677) experienced a net inflow of 96.89 million from institutional investors, with retail investors seeing a net outflow of 61.25 million [3] - Jiuan Medical (002432) had a net inflow of 39.29 million from institutional investors, while retail investors had a net inflow of 16.09 million [3]

Core Points - The Shanghai Composite Index is at 3873.15 points, above the six-month moving average, with a decline of 0.42% [1] - The total trading volume of A-shares today is 20,878.49 billion yuan [1] - A total of 128 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Stocks with the highest deviation rates include: - Aienju (6.89% deviation, 9.39% increase, trading volume 22.19%) - Kaiteng Gas (4.10% deviation, 5.45% increase, trading volume 6.84%) - Huifeng Diamond (3.82% deviation, 10.50% increase, trading volume 19.75%) [1] - Other stocks that just crossed the six-month line include: - Two-sided Needle, China Merchants Securities, and Guangji Pharmaceutical with minimal deviation rates [1] Trading Data - The trading data for stocks that broke the six-month line includes: - Nanjing Public (4.20% increase, 4.78% trading volume, 6.46 yuan six-month line, 6.70 yuan latest price, 3.79% deviation) - Ji'an Medical (4.19% increase, 3.45% trading volume, 38.37 yuan six-month line, 39.79 yuan latest price, 3.70% deviation) [1] - The overall trading activity reflects a diverse range of stocks with varying performance metrics [1]

Core Viewpoint - The A-share market shows a positive trend with the Shanghai Composite Index closing at 3897.56 points, above the six-month moving average, reflecting a slight increase of 0.21% [1] Group 1: Market Performance - The total trading volume of A-shares reached 1681.524 billion yuan today [1] - A total of 127 A-shares have surpassed the six-month moving average, indicating a bullish sentiment in the market [1] Group 2: Individual Stock Performance - Stocks with significant deviations from the six-month moving average include: - Ainanju (证券代: 920770) with a deviation rate of 9.77% and a daily increase of 12.36% [1] - Huifeng Diamond (证券代: 920725) with a deviation rate of 5.80% and a daily increase of 12.63% [1] - Kaitian Gas (证券代: 920010) with a deviation rate of 5.69% and a daily increase of 7.07% [1] - Other notable stocks with smaller deviations include Jiangzhong Pharmaceutical, Qingdao Port, and Ningbo Energy, which have just crossed the six-month moving average [1]

Core Points - The Shanghai Composite Index is at 3906.88 points, above the six-month moving average, with a gain of 0.45% [1] - A total trading volume of A-shares reached 1,197.71 billion yuan today [1] - 158 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The stocks with the highest deviation rates from the six-month moving average include: - Aienju (11.21% deviation, latest price 21.46 yuan) [1] - Huifeng Diamond (8.50% deviation, latest price 31.92 yuan) [1] - Jiuan Medical (4.78% deviation, latest price 40.21 yuan) [1] - Other stocks that have just crossed the six-month moving average include: - Ningbo Energy, China National Heavy Duty Truck Group, and Tongda Shares [1] Trading Data - The trading data for stocks that broke the six-month moving average on October 14 includes: - Aienju: 13.85% increase, 18.54% turnover rate [1] - Huifeng Diamond: 15.53% increase, 14.22% turnover rate [1] - Jiuan Medical: 5.29% increase, 2.42% turnover rate [1] - Additional stocks with notable performance include: - Chutianlong (4.88% increase) and Daqian Ecology (5.04% increase) [1]

Group 1 - The National Development and Reform Commission will hold a press conference to discuss the achievements of grain circulation reform during the 14th Five-Year Plan period [1] - Microsoft has stopped providing security updates and technical support for Windows 10, increasing the risk of cyberattacks for users [2] - A total of 2.15 billion yuan worth of restricted shares will be unlocked today, with major contributions from Zhaoyi Innovation and Dingyang Technology [3] Group 2 - 15 companies have disclosed their stock repurchase progress, with significant amounts proposed by several firms, including China Merchants Industry and Jiuan Medical [4] - Economic data such as the Eurozone ZEW Economic Sentiment Index and the UK's unemployment rate for September will be released [5]

Group 1 - New stock subscription for He Yuan Biological with a subscription code of 787765 and an issue price of 29.06 yuan per share, with a subscription limit of 14,000 shares [4] - China's Ministry of Foreign Affairs clarified that recent export control measures regarding rare earths are unrelated to Pakistan, emphasizing the government's legal basis for these actions [4] - As of October 13, domestic gasoline and diesel prices have been reduced by 75 yuan and 70 yuan per ton, respectively [4] - In the first three quarters of this year, China's total goods trade import and export value reached 33.61 trillion yuan, a year-on-year increase of 4%, with exports at 19.95 trillion yuan (up 7.1%) and imports at 13.66 trillion yuan (down 0.2%) [4] - The 2025 Nobel Prize in Economic Sciences was awarded to Joel Mokyr, Philippe Aghion, and Peter Howitt for their contributions to understanding innovation-driven economic growth [4] - The 2025 Financial Street Forum will be held in Beijing from October 27 to 30, focusing on global financial development under the theme of "Innovation, Transformation, and Reshaping" [4] Group 2 - Apple CEO Tim Cook announced the pre-order for iPhone Air starting on October 17 and official sales on October 22 during a live stream on Douyin, marking his first direct interaction with Chinese consumers through this platform [5] - COMEX gold futures rose by 3.24% to $4,130 per ounce, while silver futures increased by 7.47% to $50.775 per ounce [5] - Major U.S. stock indices saw collective gains, with the Dow Jones up 1.29%, Nasdaq up 2.21%, and S&P 500 up 1.56%, while the Nasdaq Golden Dragon China Index rose by 3.21% [5] Group 3 - Zhitian Tui's stock will be delisted on October 14 [8] - Hezhuan Intelligent has not generated any revenue from nuclear fusion-related business [9] - Yiyi Co. is planning to issue shares and pay cash to acquire assets, leading to a suspension of trading starting October 14 [10] - Gaode Infrared received a bid notification for a specific model of infrared observation instrument [11] - Chujian New Materials expects a net profit increase of 2057.62% to 2242.56% year-on-year for the first three quarters [12] - Xinhua Insurance anticipates a net profit increase of 45% to 65% year-on-year for the first three quarters [15] - Tian'ao Electronics expects a net profit increase of 1281.13% to 1475.39% year-on-year for the third quarter [16] - Sanmei Co. expects a net profit increase of 171.73% to 193.46% year-on-year for the first three quarters, driven by a significant rise in the average price of fluorinated refrigerants [17] Group 4 - Guotai Junan believes trade frictions may increase short-term oil price volatility, but a rebound in oil prices is possible after disputes, while anticipating continued oversupply in the oil market through 2026 [21] - CITIC Securities reports that recent export controls on rare earths will strengthen supply rigidity, with a favorable supply-demand balance expected as the traditional peak season approaches [22]

Group 1 - Jiuan Medical plans to repurchase shares worth no less than 300 million yuan and no more than 600 million yuan, with a maximum repurchase price of 53.5 yuan per share, to maintain company value and shareholder rights [1] - The current share price of 38.19 yuan represents a discount of approximately 28% compared to the repurchase cap, signaling potential valuation recovery [1] - The repurchased shares are intended to be sold within 12 months after the announcement, providing short-term price stability and future funding flexibility for business transformation [1] Group 2 - Lingbei's drug Bexicaserin has been recognized as a breakthrough therapy by the National Medical Products Administration (NMPA) in China for treating developmental epileptic encephalopathy (DEE) [2] - Bexicaserin is a novel oral 5-HT2C receptor agonist designed to reduce cardiovascular risks, marking a significant milestone in Lingbei's development in China [2] Group 3 - Four Rings Pharmaceutical has announced an investment in Swiss medical aesthetics company Suisselle SA, strengthening their long-term partnership [3] - This investment allows Four Rings to maintain exclusive rights to the CELLBOOSTER® product in China and participate deeply in its operations and development [3] - The collaboration aims to accelerate the promotion and sales of Four Rings' self-developed aesthetic products in Europe and other overseas markets [3] Group 4 - Fudan Zhangjiang's application for the drug Obechol acid tablets for treating primary biliary cholangitis was not approved by the NMPA due to non-compliance with registration requirements [4] - The project has incurred approximately 125 million yuan in R&D investment, which will not significantly impact the company's current financial status [4] - The company needs to review the reasons for the rejection and optimize its pipeline to enhance future R&D efficiency [4] Group 5 - Sunshine Nuohuo's BTP4507 has received approval for clinical trials from the NMPA, targeting primary hypertension patients with inadequate response to monotherapy [5] - BTP4507 is a compound formulation designed to address multiple hypertension targets, catering to the needs of over 300 million hypertensive patients in China [5] - If successful in clinical trials, this drug could open new growth avenues for the company, although it will face competition from similar combination therapies [5]